Efficacy and Safety of Concomitant Chemoradiotherapy with Cisplatin and Docetaxel in Patients with Locally Advanced Squamous Cell Head and Neck Cancers

Basit Öğe Kaydı
dc.contributor.authorBaykara, Meltem
dc.contributor.authorBuyukberber, Suleyman
dc.contributor.authorOzturk, Banu
dc.contributor.authorCoskun, Ugur
dc.contributor.authorUnsal, Diclehan Kilic
dc.contributor.authorDemirci, Umut
dc.contributor.authorDane, Faysal
dc.date.accessioned2024-04-24T17:28:17Z
dc.date.available2024-04-24T17:28:17Z
dc.date.issued2013
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground: Chemoradiation (CRT) using cisplatin-based regimens has become the standard of care in the treatment of squamous cell head and neck cancers (SCHNC). The impact of taxanes as radiosensitizing agents with concurrent CRT regimens is unknown. We therefore retrospectively evaluated the efficacy and tolerability of a weekly cisplatin+docetaxel combination with CRT in locally advanced SCHNC. Methods: Sixty-six patients with locally advanced SCHNC (39.4% stage IV, 53% stage III, and 7.6% stage II) were assessed retrospectively. Total radiation dose to the PTV of gross disease (primary and/or node) was 70 Gy/35 fractions, 5 fractions per week. Minimum doses of 60 Gy and 50 Gy were administered to PTVs of elective high risk and low risk disease, respectively. Chemotherapy (CT) consisted of weekly cisplatin (20 mg/m(2))+docetaxel (20 mg/m(2)) concurrently with RT. Results: The median age of the patients was 58 years (range, 32-77). Objective response rate was 83.3%. The 2-year progression-free survival (PFS) and overall survival (OS) were 75.7% and 78.3%, respectively. The most common grade 3 and 4 toxicities were mucositis (36.4%), nausea and vomiting (12.1%), neutropenia (4.5%). Conclusion: Weekly cisplatin and docetaxel concurrent with RT for locally advanced SCHNC was found tolerable with high efficacy.en_US
dc.identifier.doi10.7314/APJCP.2013.14.4.2557
dc.identifier.endpage2561en_US
dc.identifier.issn1513-7368
dc.identifier.issue4en_US
dc.identifier.pmid23725174
dc.identifier.scopus2-s2.0-84880296848
dc.identifier.scopusqualityQ3
dc.identifier.startpage2557en_US
dc.identifier.urihttps://doi.org/10.7314/APJCP.2013.14.4.2557
dc.identifier.urihttps://hdl.handle.net/11468/20389
dc.identifier.volume14en_US
dc.identifier.wosWOS:000322198700071
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherAsian Pacific Organization Cancer Preventionen_US
dc.relation.ispartofAsian Pacific Journal of Cancer Prevention
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectSquamous Cell Head And Neck Cancersen_US
dc.subjectChemoradiotherapyen_US
dc.subjectCisplatinen_US
dc.subjectDocetaxelen_US
dc.subjectSafetyen_US
dc.titleEfficacy and Safety of Concomitant Chemoradiotherapy with Cisplatin and Docetaxel in Patients with Locally Advanced Squamous Cell Head and Neck Cancersen_US
dc.titleEfficacy and Safety of Concomitant Chemoradiotherapy with Cisplatin and Docetaxel in Patients with Locally Advanced Squamous Cell Head and Neck Cancers
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu